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OBJECTIVE: To determine the relative cost-effectiveness of
insulin glulisine versus other rapid- and short acting insulins in
patients with Type 2 (T2DM) diabetes applied in a Polish
setting. METHODS: Treatment effects were extracted from
identiﬁed RCTs assessing the effects of insulin glulisine in
patients with diabetes. The analysis was performed from the
health care payer (Polish NHF and patient) perspective, with a
time horizon of one year. Cost-utility analysis (CUA) was per-
formed for the comparison of insulin glulisine and regular
human insulin (RHI). In the absence of signiﬁcant difference in
clinical effectiveness, cost-minimization analysis (CMA) of
insulin glulisine versus other analogs (lispro, aspart) was
chosen. A range of sensitivity analyses were performed to
account for uncertainty in input parameters. RESULTS: 1)
CUA: insulin glulisine was associated with increased QALYs
(0.0044) resulting from reduction in nocturnal hypoglycaemia
episodes, and higher costs (181 PLN per patient) compared with
RHI, with the ICER of 41,385 PLN per QALY gained. The
ICERs were most sensitive to the change in the number of noc-
turnal hypoglycaemia episodes, and 2) CMA: the cost of insulin
glulisine treatment was lower than that of lispro and aspart
(with the 1 year difference of 77PLN and 278PLN, respec-
tively). CONCLUSION: Results of the analysis indicate that
insulin glulisine is likely to represent a good value for money in
the treatment of type 2 diabetes in Poland.
PDB28
COST-EFFECTIVENESS ANALYSIS OF DOPAMINE AGONISTS
FORTHETREATMENT OF INFERTILITY ASOCIATEDTO
HYPERPROLACTINEMIA IN MEXICO
Guillen-González S1, Diez-Canseco F1, Zapata L2,Vega-Hernández
GY3, Rivas R2, Ramírez H4, Mould-Quevedo J3, Davila-Loaiza G3
1ISSSTE-Hospital 20 de Noviembre, Mexico City, Mexico, 2Guia Mark,
México, DF, Mexico, 3Pﬁzer Mexico, Mexico City, Mexico, 4Guiamark
SC, Mexico City, Mexico
OBJECTIVE: An excess of prolactin above 25 ng/mL (hyperpro-
lactinemia) can be identiﬁed in up to 10% of the population and
in women is cause of infertility. The purpose of the study was to
model the economic and health consequences of cabergoline,
bromocriptine and the sequential therapy (ST) (deﬁned as the
treatment initiated with bromocriptine followed by cabergoline)
in the management of women with hyperprolactinemia who
desired to be pregnant from the health care payer’s perspective.
METHODS: A cost-effectiveness analysis was developed using a
Bayesian decision-tree model. The model simulates costs and
effectiveness outcomes in a 31-months period. Effectiveness
measure was the percentage of women who got pregnant during
the analysis period. The comparators were cabergoline (0.5 mg
twice a week), bromocriptine (5 mg/24 hrs) and sequential
therapy. Resource use and cost data were obtained from hospital
records of patients (between 20–40 yrs old who previously told
their intention to get pregnant) being treated at a third-level
hospital within the Social Security Institute for State Workers
(ISSSTE) in Mexico City (n = 18). Effectiveness data and model
transition probabilities were obtained from international pub-
lished literature. Costs and health outcomes were discounted
using a 3% annual rate. The decision-tree model was calibrated
according to international guidelines. One-way and probabilistic
sensitivity analyses were performed using Monte Carlo Simula-
tion ﬁrst-order approach. RESULTS: Patients who received ST
experienced more effectiveness (43%) compared with patients
treated with cabergoline (40%) and bromocriptine (26%). Mean
costs per patient were higher with cabergoline (US$5027  500)
compared with ST (US$4356  774) and bromocriptine
(US$3955  769). The ICERs using bromocriptine as baseline
treatment, were US$2367  506 and US$7443  6376 for ST
and cabergoline, respectively. Sensitivity analyses showed that
cabergoline could be a cost-saving therapy reducing its price in
18% (p < 0.05). CONCLUSION: In Mexico, ST demonstrated
to be a cost-effective strategy for the treatment of infertility
associated to hyperprolactinemia in women who want to get
pregnant.
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OBJECTIVE: Hyperprolactinemia is a clinical condition char-
acterized by consistent elevation of plasmatic prolactin levels
above 25 ng/mL. The aim of this analysis was to estimate the
cost-effectiveness ratios of cabergoline, bromocriptine and the
sequential therapy (deﬁned as the treatment initiated with bro-
mocriptine followed by cabergoline) in patients with hyperpro-
lactinemia caused by hypophyseal microadenoma within the
Social Security Institute for State Workers (ISSSTE).
METHODS: A cost-effectiveness analysis was developed using
a Bayesian decision-tree model from the Mexican payer’s per-
spective. The model simulates costs and effectiveness in a
31-months period. Effectiveness measure was the number of
months with prolactin levels controlled. Efﬁcacy data and
model transition probabilities were obtained from international
literature. The comparators were cabergoline (0.5 mg twice a
week), bromocriptine (5 mg/day) and sequential therapy.
Resource use data and cost were obtained from hospital
records of patients being treated at a third-level hospital from
ISSSTE in Mexico City (n = 43). Costs and health outcomes
were discounted using a 3% annual rate. One-way and proba-
bilistic sensitivity analyses were performed using the Monte
Carlo Simulation ﬁrst-order approach. RESULTS: Cabergoline,
yielded 27.9 months of patients with prolactin levels controlled
followed by the sequential therapy with 20.3 months and bro-
mocriptine (17.7 months). The mean treatment costs were
US$5046  504 for cabergoline; US$4341  789 for the
sequential therapy and US$3937  785 for treatment with bro-
mocriptine. ICERs estimated using bromocriptine as the base-
line treatment were US$103  89 and US$151  32 for
cabergoline and sequential therapy, respectively. Based on the
one-way sensitivity analysis, cabergoline strategy could be a
cost-saving therapy with a reduction of 27% in its price. Proba-
bilistic sensitivity analyses showed that carbergoline was the
treatment more cost-effective (p < 0.05). CONCLUSION: In
Mexico, cabergoline treatment was the most cost-effective alter-
native because of its higher number of months with prolactin
levels controlled and surgeries avoided. These results should be
taken into account by Mexican health professionals in the man-
agement of hyperprolactinemia.
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